• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Mineralys Therapeutics Inc.

    3/17/25 7:58:15 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MLYS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)


    MINERALYS THERAPEUTICS, INC.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    603170101

    (CUSIP Number)


    Peter Kolchinsky
    RA Capital Management, L.P., 200 Berkeley Street, 18th Floor
    Boston, MA, 02116
    617.778.2500

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    03/13/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    603170101


    1 Name of reporting person

    RA Capital Management, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    6,287,597.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    6,287,597.00
    11Aggregate amount beneficially owned by each reporting person

    6,287,597.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    9.9 %
    14Type of Reporting Person (See Instructions)

    IA, PN



    SCHEDULE 13D

    CUSIP No.
    603170101


    1 Name of reporting person

    Peter Kolchinsky
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    6,287,597.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    6,287,597.00
    11Aggregate amount beneficially owned by each reporting person

    6,287,597.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    9.9 %
    14Type of Reporting Person (See Instructions)

    HC, IN



    SCHEDULE 13D

    CUSIP No.
    603170101


    1 Name of reporting person

    Rajeev Shah
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF, OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    6,287,597.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    6,287,597.00
    11Aggregate amount beneficially owned by each reporting person

    6,287,597.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    9.9 %
    14Type of Reporting Person (See Instructions)

    HC, IN



    SCHEDULE 13D

    CUSIP No.
    603170101


    1 Name of reporting person

    RA Capital Healthcare Fund, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    4,358,979.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    4,358,979.00
    11Aggregate amount beneficially owned by each reporting person

    4,358,979.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    6.9 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, par value $0.0001 per share
    (b)Name of Issuer:

    MINERALYS THERAPEUTICS, INC.
    (c)Address of Issuer's Principal Executive Offices:

    150 N. Radnor Chester Road, Suite F200, Radnor, PENNSYLVANIA , 19087.
    Item 1 Comment:
    Item 1 of the Statement is amended and supplemented as follows: This Amendment No. 2 (this "Amendment No. 2" or this "13D/A") amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") on February 24, 2023, and amended on February 12, 2024 (as amended, the "Statement") by the Reporting Persons. Unless otherwise defined herein, capitalized terms used in this Amendment No. 2 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged.
    Item 2.Identity and Background
    (a)
    This Amendment No. 2 is being filed on behalf of RA Capital Management, L.P. ("RA Capital"), Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the "Fund"), who are collectively referred to herein as the "Reporting Persons." The agreement among the Reporting Persons to file this 13D/A jointly in accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended (the "Act"), is attached hereto as Exhibit 99.1. The Reporting Persons' ownership of the Issuer's securities includes (i) 4,280,051 shares of common stock held directly by the Fund; (ii) 1,867,229 shares of common stock held by RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"); and (iii) a total of 49,796 shares underlying vested stock options (right to buy), and 11,593 shares underlying stock options (right to buy) which shall vest within 60 days of this filing held by Dr. Derek DiRocco for the benefit of RA Capital. The Fund also holds Pre-Funded Warrants (as defined below) through which it has a right to acquire 549,755 shares of common stock. The Pre-Funded Warrants contain a provision (the "Beneficial Ownership Blocker") which precludes exercise of the warrants to the extent that, following exercise, the Fund, together with its affiliates and other attribution parties, would own more than 9.99% of the common stock outstanding. The Reporting Persons are currently prohibited from exercising the Pre-Funded Warrants to the extent that the exercise would result in beneficial ownership of more than 6,287,597 shares of common stock by the Reporting Persons. RA Capital Healthcare Fund GP, LLC is the general partner of the Fund and RA Capital Nexus Fund III GP, LLC is the general partner of the Nexus Fund III. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and the Nexus Fund III and may be deemed a beneficial owner, for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Act"), of any securities of the Issuer held by the Fund or the Nexus Fund III. The Fund and the Nexus Fund III have delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund's and the Nexus Fund III's portfolio, including the shares of the Issuer's common stock reported herein. Because the Fund and the Nexus Fund III have divested themselves of voting and investment power over the reported securities they hold and may not revoke that delegation on less than 61 days' notice, the Fund and the Nexus Fund III disclaim beneficial ownership of the securities they hold for purposes of Section 13(d) of the Act and therefore disclaim any obligation to report ownership of the reported securities under Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13D other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13D shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.
    (b)
    The address of the principal business office of each of the Reporting Persons is 200 Berkeley Street, 18th Floor, Boston, MA 02116.
    (c)
    The Fund is a private investment vehicle. RA Capital provides investment management services to the Fund and the Nexus Fund III. The principal occupation of Dr. Kolchinsky and Mr. Shah is investment management.
    (d)
    During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
    (e)
    During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree of final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (f)
    See Item 6 of the cover pages.
    Item 3.Source and Amount of Funds or Other Consideration
     
    Item 3 of the Statement is hereby amended and supplemented as follows: On March 13, 2025, the Fund purchased 1,296,296 shares of common stock at a price of $13.50 per share from the underwriters of the Issuer's public offering (the "2025 Offering"). The aggregate purchase price for all securities acquired by the Fund in the 2025 Offering was $17,499,996, which was funded by the working capital of the Fund.
    Item 5.Interest in Securities of the Issuer
    (a)
    Rows 11 and 13 of each Reporting Person's cover page to this Schedule 13D set forth the aggregate number of shares of common stock and percentages of the shares of common stock beneficially owned by such Reporting Person and are incorporated by reference. The percentage set forth in each row 13 is based upon the sum of: (i) 49,835,637 shares of common stock outstanding as of February 7, 2025, as reported in the Issuer's Annual Report on Form 10-K filed with the SEC on February 12, 2025 and (ii) 12,962,962 shares of common stock issued in the 2025 Offering as disclosed in the Issuer's prospectus supplement dated March 11, 2025 filed with the SEC on March 12, 2025, and giving effect to stock options and Pre-Funded Warrants, to the extent exercisable within 60 days hereof, as referenced herein. Due to field limitations of the EDGAR filing system, the percentages listed in Row 13 of each of the cover pages for RA Capital, Dr. Kolchinsky and Mr. Shah have been rounded down to 9.9%.
    (b)
    Rows 7 through 10 of each Reporting Person's cover page to this Schedule 13D/A set forth the number of shares of common stock as to which such Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition and are incorporated by reference.
    (c)
    Except as set forth below, none of the Reporting Persons has effected any transactions with respect to the securities of the Issuer during the past sixty days: No. Price Per Transaction Purchaser Date Shares Share Vest Stock Option (Right to Buy) RA Capital 01/22/2025 1,833 (1) Vest Stock Option (Right to Buy) RA Capital 02/09/2025 1,222 (2) Vest Stock Option (Right to Buy) RA Capital 02/22/2025 1,833 (1) Vest Stock Option (Right to Buy) RA Capital 03/09/2025 1,222 (2) Vest Stock Option (Right to Buy) RA Capital 03/13/2025 2,741 (3) Purchase (2025 Offering) Fund 03/13/2025 1,296,296 $13.50 Vest Stock Option (Right to Buy) RA Capital 03/22/2025 1,833 (1)(4) Vest Stock Option (Right to Buy) RA Capital 04/09/2025 1,222 (2)(4) Vest Stock Option (Right to Buy) RA Capital 04/13/2025 2,742 (3)(4) Vest Stock Option (Right to Buy) RA Capital 04/22/2025 1,833 (1)(4) Vest Stock Option (Right to Buy) RA Capital 05/09/2025 1,222 (2)(4) Vest Stock Option (Right to Buy) RA Capital 05/13/2025 2,741 (3)(4) (1) This option represents a right to purchase a total of 22,000 shares of the Issuer's common stock, which began vesting on June 22, 2024 in 12 substantially equal monthly installments, subject to DiRocco's continued service to the Issuer through each vesting date. In the event that the next annual meeting of stockholders occurs prior to May 22, 2025, any remaining unvested portion of the stock option award will vest on the date of such meeting. These options have an exercise price of $12.52. (2) This option represents a right to purchase a total of 44,000 shares of the Issuer's common stock, which began vesting on March 9, 2023 in 36 equal monthly installments, subject to DiRocco's continued service to the Issuer through each vesting date. These options have an exercise price of $16.00. (3) This option represents a right to purchase a total of 32,900 shares of the Issuer's common stock, which began vesting on March 13, 2025 in 12 equal monthly installments, subject to DiRocco's continued service to the Issuer through each vesting date. These options have an exercise price of $10.20. (4) Represents future vesting options within 60 days from the filing date of this Amendment No. 2.
    (d)
    Except as set forth below, none of the Reporting Persons has effected any transactions with respect to the securities of the Issuer since the most recent amendment to this Schedule 13D/A.
    (e)
    Not applicable.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    Item 6 of the Statement is hereby amended and supplemented as follows: Lock-up Agreement Each of the Issuer's executive officers and directors, including Dr. DiRocco, have agreed not to sell or transfer any common stock or securities convertible into, exchangeable for, exercisable for, or repayable with common stock, for 60 days from March 11, 2025 without first obtaining the written consent of BofA Securities, Inc., Evercore Group L.L.C. and Goldman Sachs & Co. LLC, subject to specified exceptions, including sales pursuant to existing trading plans established under Rule 10b5-1 under the Exchange Act.
    Item 7.Material to be Filed as Exhibits.
     
    Exhibit 99.1 Joint Filing Agreement Exhibit 99.2 Form of Lock-up From Directors and Officers (incorporated by reference to Exhibit A to the Underwriting Agreement filed as Exhibit 1.1 to the Issuer's Current Report on Form 8-K, filed with the SEC on March 12, 2025).

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    RA Capital Management, L.P.
     
    Signature:/s/ Peter Kolchinsky
    Name/Title:By Peter Kolchinsky, Authorized Signatory
    Date:03/17/2025
     
    Peter Kolchinsky
     
    Signature:/s/ Peter Kolchinsky
    Name/Title:Peter Kolchinsky
    Date:03/17/2025
     
    Rajeev Shah
     
    Signature:/s/ Rajeev Shah
    Name/Title:Rajeev Shah
    Date:03/17/2025
     
    RA Capital Healthcare Fund, L.P.
     
    Signature:/s/ Peter Kolchinsky
    Name/Title:By RA Capital Healthcare Fund GP, LLC, its General Partner, By Peter Kolchinsky, Manager
    Date:03/17/2025
    Get the next $MLYS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MLYS

    DatePrice TargetRatingAnalyst
    6/11/2025$15.00Hold
    Jefferies
    7/10/2024$30.00Buy
    H.C. Wainwright
    4/2/2024$30.00Buy
    Goldman
    3/7/2023Outperform
    Evercore ISI
    3/7/2023$39.00Buy
    BofA Securities
    3/7/2023$32.00Buy
    Guggenheim
    3/7/2023$27.00Overweight
    Wells Fargo
    3/7/2023$45.00Buy
    Stifel
    More analyst ratings

    $MLYS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Rodman David Malcom exercised 2,171 shares at a strike of $16.00 and sold $65,586 worth of shares (2,171 units at $30.21) (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    2/11/26 6:58:56 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Rodman David Malcom exercised 416 shares at a strike of $15.44 and sold $13,354 worth of shares (416 units at $32.10) (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    1/20/26 8:33:56 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Rodman David Malcom exercised 7,709 shares at a strike of $12.39 and sold $623,115 worth of shares (19,076 units at $32.66), decreasing direct ownership by 18% to 50,437 units (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    1/15/26 7:07:36 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    SEC Filings

    View All

    SEC Form 144 filed by Mineralys Therapeutics Inc.

    144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)

    2/9/26 4:20:45 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Mineralys Therapeutics Inc.

    SCHEDULE 13G - Mineralys Therapeutics, Inc. (0001933414) (Subject)

    2/5/26 1:31:51 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Mineralys Therapeutics Inc.

    144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)

    1/20/26 4:26:57 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    RADNOR, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on February 9, 2026, the Compensation Committee of Mineralys' Board of Directors granted inducement stock option awards covering 33,504 shares and inducement restricted stock unit awards covering 25,128 shares of Mineralys common stock to two new non-executive employees. The awards were granted under Mineralys' 2025 Employment Inducemen

    2/11/26 7:00:40 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026

    RADNOR, Pa., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today issued a corporate update highlighting several recent and upcoming clinical and regulatory milestones. In addition, the Company announced that its management team will participate in the 15th LifeSci Partners Corporate Access event taking place January 12-14, 2026, in San Francisco, California. "As we reflect on the data generated with lorundrostat to

    1/6/26 8:00:00 AM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

    RADNOR, Pa., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on November 24, 2025, the Compensation Committee of Mineralys' Board of Directors granted an inducement stock option award covering 146,000 shares of Mineralys common stock to one new non-executive employee. The award was granted under Mineralys' 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity

    11/26/25 4:05:00 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Akkaraju Srinivas bought $14,999,992 worth of shares (588,235 units at $25.50) (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    9/8/25 8:07:14 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ra Capital Management, L.P. bought $29,999,985 worth of shares (1,176,470 units at $25.50) (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    9/8/25 5:59:46 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Slingsby Brian Taylor bought $3,499,996 worth of shares (259,259 units at $13.50) (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    4/25/25 7:01:59 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Mineralys Therapeutics with a new price target

    Jefferies initiated coverage of Mineralys Therapeutics with a rating of Hold and set a new price target of $15.00

    6/11/25 7:54:20 AM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Mineralys Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Mineralys Therapeutics with a rating of Buy and set a new price target of $30.00

    7/10/24 7:50:59 AM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Mineralys Therapeutics with a new price target

    Goldman initiated coverage of Mineralys Therapeutics with a rating of Buy and set a new price target of $30.00

    4/2/24 7:34:24 AM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Financials

    Live finance-specific insights

    View All

    Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    – Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 – – Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced financial results for the third quarter ended September 30, 2025, and provided a corporate update. "We are at an excitin

    11/10/25 4:05:00 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025

    RADNOR, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the third quarter ended September 30, 2025, after the financial markets close on Monday, November 10, 2025. Monday, November 10th @ 4:30 p.m. ETDomestic:1-877-704-4453International:1-201-389-0920Conference ID:13756051Webcast:Webcast Link A live webcast of the conference call may also be found on the "

    11/3/25 8:00:00 AM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    – Presented and published the positive results from both the Launch-HTN and Advance-HTN pivotal trials at scientific meetings and in JAMA and NEJM – – Pre-NDA meeting scheduled to take place in 4Q 2025 – – Explore-CKD Phase 2 trial successfully achieved statistical significance in reduction of systolic BP and UACR, and demonstrated a favorable safety profile – – Explore-OSA Phase 2 trial in OSA participants with hypertension is ongoing; topline results anticipated in 1H 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to

    8/12/25 4:05:00 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Leadership Updates

    Live Leadership Updates

    View All

    Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer

    RADNOR, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced the appointment of Minji Kim, Ph.D. as Chief Business Officer. Adam Levy will remain in his role as Chief Financial Officer. "With our expanding operations, we have decided to split the functions of Chief Financial Officer and Chief Business Officer into two roles, and we are excited to have Minji join our team. She brings a solid track record of generating value for multiple companies by identify

    1/4/24 4:05:00 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Bioresearch Expands its Board of Directors with Appointment of Adam Levy

    LOS ANGELES, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Praxis Bioresearch ("Praxis"), a biopharmaceutical company focused on the discovery and development of therapeutics for chronic neuropsychiatric and neurodegenerative disorders with an initial focus on apathy in Alzheimer's Disease, today announced the appointment of Adam Levy to its Board of Directors (the "Board"). Mr. Levy brings executive, financial and operational leadership experience in biopharmaceuticals. "We are excited to have Adam join our Board and support our mission to improve the lives of patients with Alzheimer's Disease," said Sandeep Patil, MD PhD, chief executive officer of Praxis Bioresearch. "Adam brings an impressive

    9/19/23 4:00:00 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mineralys Therapeutics Inc.

    SC 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)

    11/13/24 4:27:48 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mineralys Therapeutics Inc.

    SC 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)

    11/13/24 4:19:46 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mineralys Therapeutics Inc.

    SC 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)

    11/13/24 4:09:56 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care